{ "instance": { "bhvn-20220630.htm": { "axisCustom": 1, "axisStandard": 26, "contextCount": 363, "dts": { "calculationLink": { "local": [ "bhvn-20220630_cal.xml" ] }, "definitionLink": { "local": [ "bhvn-20220630_def.xml" ] }, "inline": { "local": [ "bhvn-20220630.htm" ] }, "labelLink": { "local": [ "bhvn-20220630_lab.xml" ] }, "presentationLink": { "local": [ "bhvn-20220630_pre.xml" ] }, "schema": { "local": [ "bhvn-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 699, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 13, "http://xbrl.sec.gov/dei/2022": 5, "total": 18 }, "keyCustom": 130, "keyStandard": 337, "memberCustom": 50, "memberStandard": 32, "nsprefix": "bhvn", "nsuri": "http://www.biohavenpharma.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - COVER", "role": "http://www.biohavenpharma.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118105 - Disclosure - Balance Sheet Components", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Acquisitions", "role": "http://www.biohavenpharma.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Liability Related to Sale of Future Royalties, net", "role": "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnet", "shortName": "Liability Related to Sale of Future Royalties, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131108 - Disclosure - Mandatorily Redeemable Preferred Shares, net", "role": "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnet", "shortName": "Mandatorily Redeemable Preferred Shares, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135109 - Disclosure - Shareholders' Deficit", "role": "http://www.biohavenpharma.com/role/ShareholdersDeficit", "shortName": "Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - Share-Based Compensation", "role": "http://www.biohavenpharma.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Net Loss Per Share", "role": "http://www.biohavenpharma.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151113 - Disclosure - Collaboration, License and Other Agreements", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreements", "shortName": "Collaboration, License and Other Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160114 - Disclosure - Debt", "role": "http://www.biohavenpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165115 - Disclosure - Commitments and Contingencies", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172116 - Disclosure - Income Taxes", "role": "http://www.biohavenpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Marketable Securities (Tables)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319303 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:ScheduleOfLiabilityForSaleOfFutureRoyaltiesReductionToResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327304 - Disclosure - Liability Related to Sale of Future Royalties (Tables)", "role": "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables", "shortName": "Liability Related to Sale of Future Royalties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:ScheduleOfLiabilityForSaleOfFutureRoyaltiesReductionToResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i5fc092926d7f43b4b1e8f1b6028db52f_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332305 - Disclosure - Mandatorily Redeemable Preferred Shares, net (Tables)", "role": "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables", "shortName": "Mandatorily Redeemable Preferred Shares, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i5fc092926d7f43b4b1e8f1b6028db52f_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336306 - Disclosure - Shareholders' Deficit (Tables)", "role": "http://www.biohavenpharma.com/role/ShareholdersDeficitTables", "shortName": "Shareholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343308 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.biohavenpharma.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348309 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.biohavenpharma.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:ScheduleOfMilestonePaymentsOtherAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352310 - Disclosure - Collaboration, License and Other Agreements (Tables)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTables", "shortName": "Collaboration, License and Other Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "bhvn:ScheduleOfMilestonePaymentsOtherAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361311 - Disclosure - Debt (Tables)", "role": "http://www.biohavenpharma.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2366312 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2373313 - Disclosure - Income Taxes (Tables)", "role": "http://www.biohavenpharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "id43b2441134e40698f283fdd7c5b94c7_I20220509", "decimals": "2", "first": true, "lang": "en-US", "name": "bhvn:MergerAgreementPricePerShareToBeAcquired", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)", "role": "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "shortName": "Nature of the Business and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "id43b2441134e40698f283fdd7c5b94c7_I20220509", "decimals": "2", "first": true, "lang": "en-US", "name": "bhvn:MergerAgreementPricePerShareToBeAcquired", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "shortName": "Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Marketable Securities - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails", "shortName": "Marketable Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Marketable Securities - Contractual Maturities (Details)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails", "shortName": "Marketable Securities - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Marketable Securities - Net Investment Income (Details)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails", "shortName": "Marketable Securities - Net Investment Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Marketable Securities - Proceeds and Realized Gains and Losses (Details)", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails", "shortName": "Marketable Securities - Proceeds and Realized Gains and Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ia73051b2832748259b3149fcc9b7c504_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ia73051b2832748259b3149fcc9b7c504_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ieda9b93bced24c588bb1aeb4cce703ea_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Fair Value of Financial Assets and Liabilities - Roll Forward of Aggregate Fair Value Determined by Level 3 Inputs (Details)", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails", "shortName": "Fair Value of Financial Assets and Liabilities - Roll Forward of Aggregate Fair Value Determined by Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ieda9b93bced24c588bb1aeb4cce703ea_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i5989a73013ae4ad88caa0c3e3b31eb64_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:PreferredStockSharesAuthorizedButNotIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "shortName": "Fair Value of Financial Assets and Liabilities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i5989a73013ae4ad88caa0c3e3b31eb64_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:PreferredStockSharesAuthorizedButNotIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - Fair Value of Financial Assets and Liabilities - Financial Instruments Not Measured at Fair Value (Details)", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "shortName": "Fair Value of Financial Assets and Liabilities - Financial Instruments Not Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Balance Sheet Components - Cash and Restricted Cash (Details)", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails", "shortName": "Balance Sheet Components - Cash and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Balance Sheet Components - Inventory (Details)", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails", "shortName": "Balance Sheet Components - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:PrepaidClinicalTrials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Balance Sheet Components - Prepaid Expenses (Details)", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails", "shortName": "Balance Sheet Components - Prepaid Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:PrepaidClinicalTrials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:AccruedDevelopmentMilestonePayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details)", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:AccruedDevelopmentMilestonePayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Acquisitions (Details)", "role": "http://www.biohavenpharma.com/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "iea5b0cc91d564cd597c8da7c44ea6183_D20220404-20220404", "decimals": "-6", "lang": "en-US", "name": "bhvn:AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsLeadAssetBVH7000Maximum", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i89ee3e0ba98c442aaa13633e56fc6fbb_D20210301-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Liability Related to Sale of Future Royalties, net - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "shortName": "Liability Related to Sale of Future Royalties, net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i54f19b67bc7a47b4a0ec10830b60cbd9_D20180601-20180630", "decimals": "INF", "lang": "en-US", "name": "bhvn:NumberOfUnitsOfAccountingRelatedToConsiderationReceived", "reportCount": 1, "unique": true, "unitRef": "unit_of_accounting", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "if5eb8609515148c8a5fb3dc050ffe141_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:ResearchAndDevelopmentContraExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Liability Related to Sale of Future Royalties, net - Reduction to Research and Development Expenses (Details)", "role": "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails", "shortName": "Liability Related to Sale of Future Royalties, net - Reduction to Research and Development Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "if5eb8609515148c8a5fb3dc050ffe141_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:ResearchAndDevelopmentContraExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:NoncashInterestExpenseOnFutureRoyaltiesLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - Liability Related to Sale of Future Royalties, net - Activity within Liability Account (Details)", "role": "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails", "shortName": "Liability Related to Sale of Future Royalties, net - Activity within Liability Account (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhvn:ScheduleOfLiabilityForSaleOfFutureRoyaltiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i264adb47596c48bc9be303e10d48eab5_I20211231", "decimals": "-3", "lang": "en-US", "name": "bhvn:LiabilityForSaleOfFutureRoyaltiesCarryingAmountNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Mandatorily Redeemable Preferred Shares, net - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "shortName": "Mandatorily Redeemable Preferred Shares, net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "iaf0192bac384403da27aabec70979dcc_D20190401-20190430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Mandatorily Redeemable Preferred Shares, net - Activity Within the Preferred Share Liability (Details)", "role": "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "shortName": "Mandatorily Redeemable Preferred Shares, net - Activity Within the Preferred Share Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "iad97097960f34c4ea2298655ab2bb45e_I20211231", "decimals": "-3", "lang": "en-US", "name": "bhvn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueGrossAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i1db3596de20540088bcbe5d1a48bd2d9_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437421 - Disclosure - Shareholders' Deficit - Changes in Shareholders' Deficit (Details)", "role": "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "shortName": "Shareholders' Deficit - Changes in Shareholders' Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ibe15c775477b48f3b14117efe876c4c0_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Shareholders' Deficit - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails", "shortName": "Shareholders' Deficit - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i6050fadb72da44f1ba14f4a20dc1c6e2_I20201231", "decimals": "-3", "lang": "en-US", "name": "bhvn:EquityDistributionAgreementMaximumAggregateAvailableAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i594b50f3138f4c84867e75754a47f16f_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441423 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i668e75a2c9b748d4a0b6a683e855988b_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444424 - Disclosure - Share-Based Compensation - Non-Cash Expense (Details)", "role": "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "shortName": "Share-Based Compensation - Non-Cash Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation", "role": "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i594b50f3138f4c84867e75754a47f16f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445425 - Disclosure - Share-Based Compensation - Stock Options (Details)", "role": "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails", "shortName": "Share-Based Compensation - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i594b50f3138f4c84867e75754a47f16f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:NumberOfCommonSharesToBeReceivedForVestedRestrictedStockUnit", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446426 - Disclosure - Share-Based Compensation - Restricted Share Units and Performance Share Units (Details)", "role": "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "shortName": "Share-Based Compensation - Restricted Share Units and Performance Share Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:NumberOfCommonSharesToBeReceivedForVestedRestrictedStockUnit", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449427 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)", "role": "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "shortName": "Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450428 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "role": "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453429 - Disclosure - Collaboration, License and Other Agreements - Pfizer Collaboration (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "shortName": "Collaboration, License and Other Agreements - Pfizer Collaboration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "idf184137a2f7430a9cd5235e937f96d7_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ieb277c83e5284e69b3636c93058ecdb3_D20130901-20130930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454430 - Disclosure - Collaboration, License and Other Agreements - Yale University Agreement (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "shortName": "Collaboration, License and Other Agreements - Yale University Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ieb277c83e5284e69b3636c93058ecdb3_D20130901-20130930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455431 - Disclosure - Collaboration, License and Other Agreements - BMS Agreement and Amendment (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "shortName": "Collaboration, License and Other Agreements - BMS Agreement and Amendment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i1ea1c6f19f30458b894855c7b1422205_D20200801-20200831", "decimals": "-3", "lang": "en-US", "name": "bhvn:MilestonePaymentPaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:NoncashInterestExpenseOnFutureRoyaltiesLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456432 - Disclosure - Collaboration, License and Other Agreements - RPI Agreements (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "shortName": "Collaboration, License and Other Agreements - RPI Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "icd382f108f9d40b0a9c866614ceb795d_D20180601-20180630", "decimals": "-3", "lang": "en-US", "name": "bhvn:ProceedsFromRoyaltyAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457433 - Disclosure - Collaboration, License and Other Agreements - AstraZeneca License Agreement (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "shortName": "Collaboration, License and Other Agreements - AstraZeneca License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ia8bf112b2ae94ea9a50b8ac224a8be8a_D20180901-20180930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i4f0180f02a1d4383a075cc7ba1bc0878_I20220228", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458434 - Disclosure - Collaboration, License and Other Agreements - Taldefgrobep Alfa License Agreement (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "shortName": "Collaboration, License and Other Agreements - Taldefgrobep Alfa License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i4f0180f02a1d4383a075cc7ba1bc0878_I20220228", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459435 - Disclosure - Collaboration, License and Other Agreements - Other Agreements (Details)", "role": "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "shortName": "Collaboration, License and Other Agreements - Other Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "id33a3d54afd94272bfe125717fd9ccb0_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "bhvn:ResearchAndDevelopmentExpenseMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseOther", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462436 - Disclosure - Debt - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ia3431a5d5396448ebc01c22694658bee_I20200831", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463437 - Disclosure - Debt - Summary of Borrowings (Details)", "role": "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "shortName": "Debt - Summary of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464438 - Disclosure - Debt - Repayments of Debt Principal (Details)", "role": "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails", "shortName": "Debt - Repayments of Debt Principal (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467439 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468440 - Disclosure - Commitments and Contingencies - Lease Costs (Details)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails", "shortName": "Commitments and Contingencies - Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bhvn:ScheduleOfLeaseSupplementalCashFlowInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469441 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information (Details)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails", "shortName": "Commitments and Contingencies - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bhvn:ScheduleOfLeaseSupplementalCashFlowInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bhvn:ScheduleOfLeaseAssetsAndLeaseLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470442 - Disclosure - Commitments and Contingencies - Supplemental Balance Sheet Information (Details)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails", "shortName": "Commitments and Contingencies - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bhvn:ScheduleOfLeaseAssetsAndLeaseLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471443 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i7b8ba4c183914ec79d5760f2dfa442e9_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474444 - Disclosure - Income Taxes (Details)", "role": "http://www.biohavenpharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "i71a6d50760e041948df9c0cf9fc4ffb6_D20220401-20220630", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Marketable Securities", "role": "http://www.biohavenpharma.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Fair Value of Financial Assets and Liabilities", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220630.htm", "contextRef": "ic56c388a8e3540ea924320fc6d60ad27_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 89, "tag": { "bhvn_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as clinical trial costs, due within one year or the normal operating cycle, if longer.", "label": "Accrued Clinical Trial Costs, Current", "terseLabel": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AccruedDevelopmentMilestonePayableCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Development Milestone Payable, Current", "label": "Accrued Development Milestone Payable, Current", "terseLabel": "Accrued development milestones" } } }, "localname": "AccruedDevelopmentMilestonePayableCurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AccruedExpensesPaymentToBePaidByCompanyFollowingRegulatoryApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses, Payment To Be Paid By Company Following Regulatory Approval", "label": "Accrued Expenses, Payment To Be Paid By Company Following Regulatory Approval", "terseLabel": "Accrued expense for payment due following regulatory approval" } } }, "localname": "AccruedExpensesPaymentToBePaidByCompanyFollowingRegulatoryApproval", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AccruedSalesDiscountsAndAllowances": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Sales Discounts And Allowances", "label": "Accrued Sales Discounts And Allowances", "terseLabel": "Accrued sales discounts and allowances" } } }, "localname": "AccruedSalesDiscountsAndAllowances", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AgreementTermFromInitialCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement, Term From Initial Commercial Sale", "label": "Agreement, Term From Initial Commercial Sale", "terseLabel": "Agreement term after first commercial sale" } } }, "localname": "AgreementTermFromInitialCommercialSale", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "durationItemType" }, "bhvn_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares", "terseLabel": "Stock issued in acquisition, number of shares" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_AssetAcquisitionPotentialCommercialSalesBasedMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum", "label": "Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum", "terseLabel": "Potential commercial sales based milestones of BHV-7000" } } }, "localname": "AssetAcquisitionPotentialCommercialSalesBasedMilestonePaymentsMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsKv7PipelineDevelopmentMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum", "label": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum", "terseLabel": "Potential developmental and regulatory milestones on Kv7 pipeline development" } } }, "localname": "AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsKv7PipelineDevelopmentMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsLeadAssetBVH7000Maximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum", "label": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum", "terseLabel": "Potential developmental and regulatory milestones on BHV-7000" } } }, "localname": "AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsLeadAssetBVH7000Maximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AssetAcquisitionRegulatoryMilestonePaymentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Regulatory Milestone Payment, Liability", "label": "Asset Acquisition, Regulatory Milestone Payment, Liability", "terseLabel": "Recorded liability" } } }, "localname": "AssetAcquisitionRegulatoryMilestonePaymentLiability", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Astra Zeneca", "label": "Astra Zeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_BMSAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the entity's license agreement with BMS (the \"BMS Agreement\")for the development and commercialization rights as well as other CGRP-related intellectual property.", "label": "B M S Agreement [Member]", "terseLabel": "BMS Agreement" } } }, "localname": "BMSAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "domainItemType" }, "bhvn_BMSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BMS", "label": "BMS [Member]", "terseLabel": "BMS" } } }, "localname": "BMSMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_BioShin2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioShin 2020 Equity Incentive Plan", "label": "BioShin 2020 Equity Incentive Plan [Member]", "terseLabel": "BioShin 2020 Equity Incentive Plan" } } }, "localname": "BioShin2020EquityIncentivePlanMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_BioShinLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioShin Limited", "label": "BioShin Limited [Member]", "terseLabel": "BioShin Limited" } } }, "localname": "BioShinLimitedMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_BioShinPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioShin Preferred Shares", "label": "BioShin Preferred Shares [Member]", "terseLabel": "BioShin Preferred Shares" } } }, "localname": "BioShinPreferredSharesMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_BiohavenPharmaceuticalHoldingCompanyLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biohaven Pharmaceutical Holding Company Ltd", "label": "Biohaven Pharmaceutical Holding Company Ltd [Member]", "terseLabel": "Biohaven" } } }, "localname": "BiohavenPharmaceuticalHoldingCompanyLtdMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "bhvn_BusinessCombinationCommonSharesOfAcquirerExchangedForEachShareOfAcquiree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Common Shares Of Acquirer Exchanged For Each Share Of Acquiree", "label": "Business Combination, Common Shares Of Acquirer Exchanged For Each Share Of Acquiree", "terseLabel": "Shares of common stock exchanged for each share of acquiree" } } }, "localname": "BusinessCombinationCommonSharesOfAcquirerExchangedForEachShareOfAcquiree", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital", "terseLabel": "Net working capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ChangeInObligationToPerformResearchAndDevelopmentServices": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change In Obligation To Perform Research And Development Services", "label": "Change In Obligation To Perform Research And Development Services", "negatedTerseLabel": "Change in obligation to perform R&D services" } } }, "localname": "ChangeInObligationToPerformResearchAndDevelopmentServices", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_ChannelBiosciencesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Channel Biosciences LLC", "label": "Channel Biosciences LLC [Member]", "terseLabel": "Channel" } } }, "localname": "ChannelBiosciencesLLCMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_CollaborationAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration And Other", "label": "Collaboration And Other [Member]", "terseLabel": "Collaboration and other revenue" } } }, "localname": "CollaborationAndOtherMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "domainItemType" }, "bhvn_ContingentValueRightAmountPerEachRightForRegulatoryApproval": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent Value Right, Amount Per Each Right For Regulatory Approval", "label": "Contingent Value Right, Amount Per Each Right For Regulatory Approval", "terseLabel": "Amount received per contingent value right upon regulatory approval" } } }, "localname": "ContingentValueRightAmountPerEachRightForRegulatoryApproval", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ContingentValueRightExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Value Right, Expiration term", "label": "Contingent Value Right, Expiration term", "terseLabel": "Contingent value right term period" } } }, "localname": "ContingentValueRightExpirationTerm", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "durationItemType" }, "bhvn_ContingentValueRightMaximumAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Value Right, Maximum Amount Payable", "label": "Contingent Value Right, Maximum Amount Payable", "terseLabel": "Maximum amount payable for contingent value rights" } } }, "localname": "ContingentValueRightMaximumAmountPayable", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ConversionRatePerAgreementPreferredStockToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Rate Per Agreement, Preferred Stock To Common Stock, Shares", "label": "Conversion Rate Per Agreement, Preferred Stock To Common Stock, Shares", "terseLabel": "Conversion rate of preferred stock to common stock per agreement (in shares)" } } }, "localname": "ConversionRatePerAgreementPreferredStockToCommonStockShares", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_DebtInstrumentCompanyElectionOptionForPaymentOfInterestInKindNumberOfQuarters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Company Election Option For Payment Of Interest In Kind, Number Of Quarters", "label": "Debt Instrument, Company Election Option For Payment Of Interest In Kind, Number Of Quarters", "terseLabel": "Number of fiscal quarters for Company option for interest payable in kind" } } }, "localname": "DebtInstrumentCompanyElectionOptionForPaymentOfInterestInKindNumberOfQuarters", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhvn_DebtInstrumentCompanyElectionOptionForPaymentOfInterestInKindNumberOfQuartersAfterTerminationDateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Company Election Option For Payment Of Interest In Kind, Number Of Quarters After Termination Date, Maximum", "label": "Debt Instrument, Company Election Option For Payment Of Interest In Kind, Number Of Quarters After Termination Date, Maximum", "terseLabel": "Number of fiscal quarters after termination date for Company option for interest payable in kind" } } }, "localname": "DebtInstrumentCompanyElectionOptionForPaymentOfInterestInKindNumberOfQuartersAfterTerminationDateMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhvn_DebtInstrumentCompanyElectionOptionForPercentageOfInterestPayableInKind": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Company Election Option For Percentage Of Interest Payable In Kind", "label": "Debt Instrument, Company Election Option For Percentage Of Interest Payable In Kind", "terseLabel": "Company option for percentage of interest payable in kind (percent)" } } }, "localname": "DebtInstrumentCompanyElectionOptionForPercentageOfInterestPayableInKind", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_DebtInstrumentComponentOfPrincipalAmountPreviouslyLinkedToSalesMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Component Of Principal Amount Previously Linked To Sales Milestone", "label": "Debt Instrument, Component Of Principal Amount Previously Linked To Sales Milestone", "terseLabel": "Component of principal amount previously related to sales milestone" } } }, "localname": "DebtInstrumentComponentOfPrincipalAmountPreviouslyLinkedToSalesMilestone", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_DebtInstrumentCovenantNetSalesForFourConsecutiveQuartersToWaiveMinimumUnrestrictedCashBalanceRequirement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Net Sales For Four Consecutive Quarters To Waive Minimum Unrestricted Cash Balance Requirement", "label": "Debt Instrument, Covenant, Net Sales For Four Consecutive Quarters To Waive Minimum Unrestricted Cash Balance Requirement", "terseLabel": "Net sales for four consecutive quarters to waive minimum unrestricted cash balance requirement" } } }, "localname": "DebtInstrumentCovenantNetSalesForFourConsecutiveQuartersToWaiveMinimumUnrestrictedCashBalanceRequirement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_DebtInstrumentCovenantNumberOfConsecutiveQuartersForMinimumUnrestrictedCashBalanceRequirement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Number Of Consecutive Quarters For Minimum Unrestricted Cash Balance Requirement", "label": "Debt Instrument, Covenant, Number Of Consecutive Quarters For Minimum Unrestricted Cash Balance Requirement", "terseLabel": "Number of consecutive quarters for minimum unrestricted cash balance requirement" } } }, "localname": "DebtInstrumentCovenantNumberOfConsecutiveQuartersForMinimumUnrestrictedCashBalanceRequirement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhvn_DebtInstrumentCovenantUnrestrictedCashBalanceMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Unrestricted Cash Balance, Minimum", "label": "Debt Instrument, Covenant, Unrestricted Cash Balance, Minimum", "terseLabel": "Debt covenant, minimum unrestricted cash balance" } } }, "localname": "DebtInstrumentCovenantUnrestrictedCashBalanceMinimum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_DebtInstrumentLIBORRateFloorPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, LIBOR Rate Floor, Percentage", "label": "Debt Instrument, LIBOR Rate Floor, Percentage", "terseLabel": "LIBOR rate floor (percent)" } } }, "localname": "DebtInstrumentLIBORRateFloorPercentage", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_EligibleContingentPaymentsReceivablePerAgreementSalesBasedMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Eligible Contingent Payments Receivable Per Agreement, Sales-Based Milestones", "label": "Eligible Contingent Payments Receivable Per Agreement, Sales-Based Milestones", "terseLabel": "Eligible contingent payments receivable per agreement for sales-based milestones" } } }, "localname": "EligibleContingentPaymentsReceivablePerAgreementSalesBasedMilestones", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_EquityDistributionAgreementMaximumAggregateAvailableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement, Maximum Aggregate Available, Amount", "label": "Equity Distribution Agreement, Maximum Aggregate Available, Amount", "terseLabel": "Equity Distribution Agreement aggregate amount" } } }, "localname": "EquityDistributionAgreementMaximumAggregateAvailableAmount", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement", "label": "Equity Distribution Agreement [Member]", "terseLabel": "Equity Distribution Agreement" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_FairValueAdjustmentOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the change in the fair value of the derivative that is recognized as a component of other income.", "label": "Fair Value Adjustment Of Derivative Liability", "terseLabel": "Change in fair value of derivatives" } } }, "localname": "FairValueAdjustmentOfDerivativeLiability", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_FairValueAdjustmentOfDerivatives": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value Adjustment Of Derivatives", "label": "Fair Value Adjustment Of Derivatives", "negatedLabel": "Change in fair value of derivatives" } } }, "localname": "FairValueAdjustmentOfDerivatives", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "bhvn_FinanceLeaseRightOfUseAsestModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-of-use Asest, Modification", "label": "Finance Lease, Right-of-use Asest, Modification", "terseLabel": "Finance lease right-of-use asset modification" } } }, "localname": "FinanceLeaseRightOfUseAsestModification", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinanceLeaseRightOfUseAssetModifications": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-of-Use Asset, Modifications", "label": "Finance Lease, Right-of-Use Asset, Modifications", "terseLabel": "Modifications affecting finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetModifications", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Issuance", "label": "Financial Instruments Subject To Mandatory Redemption, Issuance", "terseLabel": "Issuance of Series B preferred shares at fair value" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionIssuance", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionNoncashInterestExpenseNetOfTransactionCostAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Noncash Interest Expense Net Of Transaction Cost Amortization", "label": "Financial Instruments Subject To Mandatory Redemption, Noncash Interest Expense Net Of Transaction Cost Amortization", "terseLabel": "Interest expense recognized, net of transaction cost amortization" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionNoncashInterestExpenseNetOfTransactionCostAmortization", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionRedemptionOfPreferredShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Redemption Of Preferred Shares", "label": "Financial Instruments Subject To Mandatory Redemption, Redemption Of Preferred Shares", "negatedTerseLabel": "Redemption of Series A preferred shares" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionRedemptionOfPreferredShares", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueGrossAmount": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails": { "order": 1.0, "parentTag": "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Gross, Amount", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Gross, Amount", "periodEndLabel": "Gross balance, ending", "periodStartLabel": "Gross balance, beginning" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueGrossAmount", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Shares Issued", "label": "Financial Instruments Subject To Mandatory Redemption, Shares Issued", "terseLabel": "Mandatorily redeemable shares issued (in shares)" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSharesIssued", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Shares Outstanding", "label": "Financial Instruments Subject To Mandatory Redemption, Shares Outstanding", "terseLabel": "Mandatorily redeemable shares outstanding (in shares)" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSharesOutstanding", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_FinancialInstrumentsSubjectToMandatoryRedemptionUnamortizedTransactionCosts": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails": { "order": 2.0, "parentTag": "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial Instruments Subject To Mandatory Redemption, Unamortized Transaction Costs", "label": "Financial Instruments Subject To Mandatory Redemption, Unamortized Transaction Costs", "negatedTerseLabel": "Less: unamortized transaction costs" } } }, "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionUnamortizedTransactionCosts", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FundingAgreementParticipationRightAnnualSalesThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Funding Agreement, Participation Right, Annual Sales Threshold", "terseLabel": "Annual global net sales threshold for revenue participation right" } } }, "localname": "FundingAgreementParticipationRightAnnualSalesThreshold", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FundingAgreementParticipationRightOnGlobalAnnualSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Funding Agreement, Participation Right On Global Annual Sales, Percentage", "terseLabel": "Participation rate for revenue participation right (percent)" } } }, "localname": "FundingAgreementParticipationRightOnGlobalAnnualSalesPercentage", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_FundingAgreementPercentageOfGlobalNetSalesRimegepantForParticipationRightsBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreement, Percentage Of Global Net Sales Rimegepant For Participation Rights Basis", "label": "Funding Agreement, Percentage Of Global Net Sales Rimegepant For Participation Rights Basis", "terseLabel": "Percentage of global net sales of products containing rimegepant for basis of participation rights" } } }, "localname": "FundingAgreementPercentageOfGlobalNetSalesRimegepantForParticipationRightsBasis", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_FundingAgreementPercentageOfGlobalNetSalesZavegepantForParticipationRightsBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreement, Percentage Of Global Net Sales Zavegepant For Participation Rights Basis", "label": "Funding Agreement, Percentage Of Global Net Sales Zavegepant For Participation Rights Basis", "terseLabel": "Percentage of global net sales of products containing zavegepant for basis of participation rights" } } }, "localname": "FundingAgreementPercentageOfGlobalNetSalesZavegepantForParticipationRightsBasis", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_FundingAgreementRevenueParticipationRightAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Funding Agreement, Revenue Participation Right [Axis]", "terseLabel": "Funding Agreement, Revenue Participation Right [Axis]" } } }, "localname": "FundingAgreementRevenueParticipationRightAxis", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhvn_FundingAgreementRevenueParticipationRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Funding Agreement, Revenue Participation Right [Domain]", "terseLabel": "Funding Agreement, Revenue Participation Right [Domain]" } } }, "localname": "FundingAgreementRevenueParticipationRightDomain", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_InventoryCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Current And Noncurrent", "label": "Inventory, Current And Noncurrent", "totalLabel": "Total inventories" } } }, "localname": "InventoryCurrentAndNoncurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_InvestmentIncomeExcludingRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Excluding Realized Gain (Loss)", "label": "Investment Income, Excluding Realized Gain (Loss)", "totalLabel": "Net investment income (excluding net realized capital gains or losses)" } } }, "localname": "InvestmentIncomeExcludingRealizedGainLoss", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_KULeuvenAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KU Leuven Agreement", "label": "KU Leuven Agreement [Member]", "terseLabel": "KU Leuven Agreement" } } }, "localname": "KULeuvenAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_KatholiekeUniversiteitLeuvenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Katholieke Universiteit Leuven", "label": "Katholieke Universiteit Leuven [Member]", "terseLabel": "KU Leuven" } } }, "localname": "KatholiekeUniversiteitLeuvenMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_KleoPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the entity's equity investment in Kleo Pharmaceuticals, Inc (\"Kleo\").", "label": "Kleo Pharmaceuticals Inc [Member]", "terseLabel": "Kleo" } } }, "localname": "KleoPharmaceuticalsIncMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability, Undiscounted Excess Amount", "label": "Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Other Information", "label": "Lease, Other Information [Abstract]", "terseLabel": "Leases, Other Information" } } }, "localname": "LeaseOtherInformationAbstract", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "bhvn_LesseeLeaseLiabilityMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease Liability, Maturity", "label": "Lessee, Lease Liability, Maturity [Abstract]", "terseLabel": "Total" } } }, "localname": "LesseeLeaseLiabilityMaturityAbstract", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "bhvn_LesseeLeaseLiabilityToBePaid": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Lease, Liability, To Be Paid", "label": "Lessee, Lease, Liability, To Be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeLeaseLiabilityToBePaid", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidAfterYearFive": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, After Year Five", "label": "Lessee, Liability, To Be Paid, After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeLiabilityToBePaidAfterYearFive", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidYearFive": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, Year Five", "label": "Lessee, Liability, To Be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeLiabilityToBePaidYearFive", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidYearFour": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, Year Four", "label": "Lessee, Liability, To Be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeLiabilityToBePaidYearFour", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidYearOne": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, Year One", "label": "Lessee, Liability, To Be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeLiabilityToBePaidYearOne", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidYearThree": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, Year Three", "label": "Lessee, Liability, To Be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeLiabilityToBePaidYearThree", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LesseeLiabilityToBePaidYearTwo": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "bhvn_LesseeLeaseLiabilityToBePaid", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, To Be Paid, Year Two", "label": "Lessee, Liability, To Be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeLiabilityToBePaidYearTwo", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LiabilityForSaleOfFutureRoyaltiesCarryingAmountNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Sale Of Future Royalties, Carrying Amount, Net", "label": "Liability For Sale Of Future Royalties, Carrying Amount, Net", "periodEndLabel": "Liability related to sale of future royalties - ending balance", "periodStartLabel": "Liability related to sale of future royalties - beginning balance" } } }, "localname": "LiabilityForSaleOfFutureRoyaltiesCarryingAmountNet", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LiabilityForSaleOfFutureRoyaltiesCarryingAmountNoncurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Sale Of Future Royalties, Carrying Amount, Noncurrent", "label": "Liability For Sale Of Future Royalties, Carrying Amount, Noncurrent", "terseLabel": "Liability related to sale of future royalties, net" } } }, "localname": "LiabilityForSaleOfFutureRoyaltiesCarryingAmountNoncurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "bhvn_LiabilityForSaleOfFutureRoyaltiesInitialAmountGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Sale Of Future Royalties, Initial Amount, Gross", "label": "Liability For Sale Of Future Royalties, Initial Amount, Gross", "terseLabel": "Transaction consideration allocated to liability" } } }, "localname": "LiabilityForSaleOfFutureRoyaltiesInitialAmountGross", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LiabilityForSaleOfFutureRoyaltiesProceedsAllocatedToObligationToPerformContractualService": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Sale Of Future Royalties, Proceeds Allocated To Obligation To Perform Contractual Service", "label": "Liability For Sale Of Future Royalties, Proceeds Allocated To Obligation To Perform Contractual Service", "terseLabel": "Proceeds allocated to obligation to perform contractual services" } } }, "localname": "LiabilityForSaleOfFutureRoyaltiesProceedsAllocatedToObligationToPerformContractualService", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_LiabilityForSaleOfFutureRoyaltiesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability For Sale Of Future Royalties", "label": "Liability For Sale Of Future Royalties [Roll Forward]", "terseLabel": "Liability related to sales of future royalties" } } }, "localname": "LiabilityForSaleOfFutureRoyaltiesRollForward", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails" ], "xbrltype": "stringItemType" }, "bhvn_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Related To Sale Of Future Royalties Disclosure", "label": "Liability Related To Sale Of Future Royalties Disclosure [Text Block]", "terseLabel": "Liability Related to Sale of Future Royalties, net" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnet" ], "xbrltype": "textBlockItemType" }, "bhvn_LineOfCreditFacilityIncreaseInBorrowingCapacityDuringThePeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Increase In Borrowing Capacity During The Period", "label": "Line Of Credit Facility, Increase In Borrowing Capacity During The Period", "terseLabel": "Increase in aggregate available under facility" } } }, "localname": "LineOfCreditFacilityIncreaseInBorrowingCapacityDuringThePeriod", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MandatorilyRedeemablePreferredSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatorily Redeemable Preferred Shares", "label": "Mandatorily Redeemable Preferred Shares [Roll Forward]", "terseLabel": "Mandatorily Redeemable Preferred Shares [Roll Forward]" } } }, "localname": "MandatorilyRedeemablePreferredSharesRollForward", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "stringItemType" }, "bhvn_MandatorilyRedeemableSeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatorily Redeemable Series A Preferred Stock", "label": "Mandatorily Redeemable Series A Preferred Stock [Member]", "terseLabel": "Series A preferred shares" } } }, "localname": "MandatorilyRedeemableSeriesAPreferredStockMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "domainItemType" }, "bhvn_MandatorilyRedeemableSeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatorily Redeemable Series B Preferred Stock", "label": "Mandatorily Redeemable Series B Preferred Stock [Member]", "terseLabel": "Series B preferred shares" } } }, "localname": "MandatorilyRedeemableSeriesBPreferredStockMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "domainItemType" }, "bhvn_MergerAgreementPricePerShareToBeAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger Agreement, Price Per Share To Be Acquired", "label": "Merger Agreement, Price Per Share To Be Acquired", "terseLabel": "Price per share to be acquired (in dollars per share)" } } }, "localname": "MergerAgreementPricePerShareToBeAcquired", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "perShareItemType" }, "bhvn_MergerAgreementShareRatioPerTwoSharesNewCompanyToExistingShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger Agreement, Share Ratio Per Two Shares, New Company To Existing Shareholders", "label": "Merger Agreement, Share Ratio Per Two Shares, New Company To Existing Shareholders", "terseLabel": "Share ratio of new publicly traded company per two shares to existing shareholders" } } }, "localname": "MergerAgreementShareRatioPerTwoSharesNewCompanyToExistingShareholders", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "decimalItemType" }, "bhvn_MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements", "label": "Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements", "terseLabel": "Eligible milestone payment per agreement upon specified performance and regulatory milestones" } } }, "localname": "MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentMaximumObligationForEachProductToAchieveCommercialMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment, Maximum Obligation For Each Product To Achieve Commercial Milestone", "label": "Milestone Payment, Maximum Obligation For Each Product To Achieve Commercial Milestone", "terseLabel": "Maximum obligated payment for each licensed product to achieve commercial milestone" } } }, "localname": "MilestonePaymentMaximumObligationForEachProductToAchieveCommercialMilestone", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentPaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents.", "label": "Milestone Payment Paid By Company Upon Specified Regulatory Milestone Achievement", "terseLabel": "Upfront payment under the BMS Amendment" } } }, "localname": "MilestonePaymentPaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedCommercialMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified commercial milestones and annual royalty payments based on net sales of products from patents.", "label": "Milestone Payment to be Paid by Company Upon Specified Commercial Milestone Achievement", "terseLabel": "Commercial milestone payment to be paid" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedCommercialMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement", "label": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement", "terseLabel": "Development milestone payment to be paid" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Milestone Payment To Be Paid By Company Upon Specified Regulatory And Commercial Milestone Achievement", "terseLabel": "Milestone payment due upon achievement of specified regulatory and commercial milestones" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents.", "label": "Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement", "terseLabel": "Milestone payment to be paid upon regulatory achievement" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementForOtherThanSpecifiedProducts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents other than the specified product.", "label": "Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement for Other Than Specified Products", "terseLabel": "Milestone payment to be paid for any product other than rimegepant" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementForOtherThanSpecifiedProducts", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedSalesBasedMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Milestone Payment To Be Paid By Company Upon Specified Sales Based Milestone Achievement", "terseLabel": "Milestone payment due upon achievement of specified sales-based milestones" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedSalesBasedMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentsNetSalesThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payments, Net Sales Threshold, Percentage", "label": "Milestone Payments, Net Sales Threshold, Percentage", "terseLabel": "Net sales threshold for milestone (percent)" } } }, "localname": "MilestonePaymentsNetSalesThresholdPercentage", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "percentItemType" }, "bhvn_MilestonePaymentsRequiredCapitalizedToIntangibleAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments, Required, Capitalized To Intangible Asset", "label": "Milestone Payments, Required, Capitalized To Intangible Asset", "terseLabel": "Required milestone payments capitalized to intangible asset" } } }, "localname": "MilestonePaymentsRequiredCapitalizedToIntangibleAsset", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MinimumAnnualRoyaltyPaymentToBePaidByCompanyUponSaleOfProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product", "label": "Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product", "terseLabel": "Minimum annual royalty payment to be paid upon sale of product" } } }, "localname": "MinimumAnnualRoyaltyPaymentToBePaidByCompanyUponSaleOfProduct", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ModaAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moda Agreement", "label": "Moda Agreement [Member]", "terseLabel": "Moda Agreement" } } }, "localname": "ModaAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_ModaPharmaceuticalsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moda Pharmaceuticals LLC", "label": "Moda Pharmaceuticals LLC [Member]", "terseLabel": "Moda Pharmaceuticals LLC" } } }, "localname": "ModaPharmaceuticalsLLCMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_NoncashInterestExpenseOnFutureRoyaltiesLiability": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the noncash interest expense related to sale of future royalties.", "label": "Noncash Interest Expense On Future Royalties Liability", "negatedTerseLabel": "Interest expense on liability related to sale of future royalties", "terseLabel": "Interest expense on liability related to sale of future royalties", "verboseLabel": "Interest expense on liability related to sale of future royalties" } } }, "localname": "NoncashInterestExpenseOnFutureRoyaltiesLiability", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_NoncashInterestExpenseOnLongTermDebt": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Interest Expense On Long-Term Debt", "label": "Noncash Interest Expense On Long-Term Debt", "terseLabel": "Deferred interest paid-in-kind on long-term debt" } } }, "localname": "NoncashInterestExpenseOnLongTermDebt", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_November2020BMSAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2020 BMS Amendment", "label": "November 2020 BMS Amendment [Member]", "terseLabel": "November 2020 BMS Amendment" } } }, "localname": "November2020BMSAmendmentMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "domainItemType" }, "bhvn_NumberOfCommonSharesToBeReceivedForVestedRestrictedStockUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Common Shares To Be Received For Vested Restricted Stock Unit", "label": "Number Of Common Shares To Be Received For Vested Restricted Stock Unit", "terseLabel": "Number of common shares received per vested RSU" } } }, "localname": "NumberOfCommonSharesToBeReceivedForVestedRestrictedStockUnit", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "sharesItemType" }, "bhvn_NumberOfLicensedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of licensed products using the patent rights licensed from BMS.", "label": "Number of Licensed Products", "terseLabel": "Number of licensed products" } } }, "localname": "NumberOfLicensedProducts", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "integerItemType" }, "bhvn_NumberOfUnitsOfAccountingRelatedToConsiderationReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units Of Accounting Related To Consideration Received", "label": "Number Of Units Of Accounting Related To Consideration Received", "terseLabel": "Units of accounting related to consideration received" } } }, "localname": "NumberOfUnitsOfAccountingRelatedToConsiderationReceived", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhvn_ObligationForServicesCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligation For Services, Current", "label": "Obligation For Services, Current", "terseLabel": "Current obligation to perform R&D services" } } }, "localname": "ObligationForServicesCurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ObligationForServicesNoncurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligation For Services, Noncurrent", "label": "Obligation For Services, Noncurrent", "terseLabel": "Obligation to perform R&D services" } } }, "localname": "ObligationForServicesNoncurrent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "bhvn_OtherAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Agreements", "label": "Other Agreements [Member]", "terseLabel": "Other Agreements" } } }, "localname": "OtherAgreementsMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "domainItemType" }, "bhvn_PaymentForMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment For Milestone Achievement", "label": "Payment For Milestone Achievement", "terseLabel": "Milestone payments" } } }, "localname": "PaymentForMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PaymentForPurchaseOfPriorityReviewVoucherFromGovernment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment For Purchase Of Priority Review Voucher From Government", "label": "Payment For Purchase Of Priority Review Voucher From Government", "terseLabel": "Payment for priority review voucher" } } }, "localname": "PaymentForPurchaseOfPriorityReviewVoucherFromGovernment", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PaymentRequiredDueToAchievementOfMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Required Due To Achievement Of Milestone", "label": "Payment Required Due To Achievement Of Milestone", "terseLabel": "Payment required due to achievement of milestone" } } }, "localname": "PaymentRequiredDueToAchievementOfMilestone", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PaymentsOfRevenueParticipationRights": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Of Revenue Participation Rights", "label": "Payments Of Revenue Participation Rights", "terseLabel": "Payments under funding agreement" } } }, "localname": "PaymentsOfRevenueParticipationRights", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PaymentsOfUnderwritingDiscountsAndCommissionExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred by underwriting discounts and commissions.", "label": "Payments Of Underwriting Discounts And Commission Expense", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfUnderwritingDiscountsAndCommissionExpense", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PfizerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pfizer", "label": "Pfizer [Member]", "terseLabel": "Pfizer" } } }, "localname": "PfizerMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_PotentialCommercialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Commercial Milestone Payments, Maximum", "label": "Potential Commercial Milestone Payments, Maximum", "terseLabel": "Potential commercial milestone payments, maximum" } } }, "localname": "PotentialCommercialMilestonePaymentsMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PotentialDevelopmentalMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Developmental Milestone Payments, Maximum", "label": "Potential Developmental Milestone Payments, Maximum", "terseLabel": "Potential developmental milestone payments, maximum" } } }, "localname": "PotentialDevelopmentalMilestonePaymentsMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PotentialRegulatoryMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Regulatory Milestone Payments, Maximum", "label": "Potential Regulatory Milestone Payments, Maximum", "terseLabel": "Potential regulatory milestone payments, maximum" } } }, "localname": "PotentialRegulatoryMilestonePaymentsMaximum", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PreferredSharesHolderRedemptionValueRelativeToOriginalPurchasePriceOptionalRightChangeOfControl": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Shares, Holder, Redemption Value Relative To Original Purchase Price, Optional Right, Change Of Control", "label": "Preferred Shares, Holder, Redemption Value Relative To Original Purchase Price, Optional Right, Change Of Control", "terseLabel": "Redemption value relative to original purchase price, holder optional right on change of control" } } }, "localname": "PreferredSharesHolderRedemptionValueRelativeToOriginalPurchasePriceOptionalRightChangeOfControl", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_PreferredStockSharesAuthorizedButNotIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Shares Authorized but not Issued", "label": "Preferred Stock, Shares Authorized but not Issued", "terseLabel": "Unissued preferred shares (in shares)" } } }, "localname": "PreferredStockSharesAuthorizedButNotIssued", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_PrepaidClinicalTrials": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Clinical Trials", "label": "Prepaid Clinical Trials", "terseLabel": "Prepaid clinical trial costs" } } }, "localname": "PrepaidClinicalTrials", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PrepaidCommercialCosts": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Commercial Costs", "label": "Prepaid Commercial Costs", "terseLabel": "Prepaid commercial costs" } } }, "localname": "PrepaidCommercialCosts", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PrepaidManufacturing": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Manufacturing", "label": "Prepaid Manufacturing", "terseLabel": "Prepaid manufacturing" } } }, "localname": "PrepaidManufacturing", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ProceedsFromAcquisitionOfResearchAndDevelopmentAsset": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Acquisition of Research and Development Asset", "label": "Proceeds from Acquisition of Research and Development Asset", "terseLabel": "Acquisition of IPR&D asset" } } }, "localname": "ProceedsFromAcquisitionOfResearchAndDevelopmentAsset", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_ProceedsFromRoyaltyAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds received for royalty agreement.", "label": "Proceeds From Royalty Agreement", "terseLabel": "Proceeds from royalty agreement" } } }, "localname": "ProceedsFromRoyaltyAgreement", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ProceedsFromSaleOfSalesBasedParticipationRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale of Sales-Based Participation Rights", "label": "Proceeds From Sale of Sales-Based Participation Rights", "terseLabel": "Proceeds from sale of sales-based participation rights" } } }, "localname": "ProceedsFromSaleOfSalesBasedParticipationRights", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ProceedsFromServiceObligation": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Service Obligation", "label": "Proceeds From Service Obligation", "terseLabel": "Proceeds from obligation to perform R&D services" } } }, "localname": "ProceedsFromServiceObligation", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Agreement [Member]", "label": "RPI Agreement [Member]", "terseLabel": "RPI Agreement" } } }, "localname": "RPIAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIFundingAgreement2018And2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Funding Agreement 2018 And 2020", "label": "RPI Funding Agreement 2018 And 2020 [Member]", "terseLabel": "2018 and 2020 RPI Funding Agreements" } } }, "localname": "RPIFundingAgreement2018And2020Member", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIFundingAgreement2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Funding Agreement 2018", "label": "RPI Funding Agreement 2018 [Member]", "terseLabel": "2018 RPI Funding Agreement" } } }, "localname": "RPIFundingAgreement2018Member", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIFundingAgreement2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Funding Agreement 2020", "label": "RPI Funding Agreement 2020 [Member]", "terseLabel": "2020 RPI Funding Agreement" } } }, "localname": "RPIFundingAgreement2020Member", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIFundingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Funding Agreement [Member]", "label": "RPI Funding Agreement [Member]", "terseLabel": "2018 RPI Funding Agreement" } } }, "localname": "RPIFundingAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails" ], "xbrltype": "domainItemType" }, "bhvn_RPIPurchaseAgreement2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Purchase Agreement 2018", "label": "RPI Purchase Agreement 2018 [Member]", "terseLabel": "RPI Purchase Agreement" } } }, "localname": "RPIPurchaseAgreement2018Member", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RepaymentOfOtherLongTermDebtAndIssuanceCostFinanceLeasePaymentsAndOther": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment Of Other Long-Term Debt And Issuance Cost, Finance Lease Payments, And Other", "label": "Repayment Of Other Long-Term Debt And Issuance Cost, Finance Lease Payments, And Other", "negatedTerseLabel": "Payments for term loan, finance leases, and other" } } }, "localname": "RepaymentOfOtherLongTermDebtAndIssuanceCostFinanceLeasePaymentsAndOther", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_RepurchaseOfSharesFromConsolidatedSubsidiaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase Of Shares From Consolidated Subsidiary, Shares", "label": "Repurchase Of Shares From Consolidated Subsidiary, Shares", "terseLabel": "Repurchase of preferred shares in consolidated subsidiary (in shares)" } } }, "localname": "RepurchaseOfSharesFromConsolidatedSubsidiaryShares", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_RepurchaseOfSharesFromConsolidatedSubsidiaryValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase Of Shares From Consolidated Subsidiary, Value", "label": "Repurchase Of Shares From Consolidated Subsidiary, Value", "terseLabel": "Repurchase of preferred shares in consolidated subsidiary" } } }, "localname": "RepurchaseOfSharesFromConsolidatedSubsidiaryValue", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ResearchAndDevelopmentContraExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research And Development, Contra Expense", "label": "Research And Development, Contra Expense", "terseLabel": "Reduction to research and development expenses" } } }, "localname": "ResearchAndDevelopmentContraExpense", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ResearchAndDevelopmentExpenseMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Expense, Milestone Payments", "label": "Research And Development Expense, Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "ResearchAndDevelopmentExpenseMilestonePayments", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ResearchAndDevelopmentExpenseOtherPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Expense, Other Payments", "label": "Research And Development Expense, Other Payments", "terseLabel": "Other payments" } } }, "localname": "ResearchAndDevelopmentExpenseOtherPayments", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_RestrictedStockUnitsAndPerformanceShareUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units And Performance Share Units", "label": "Restricted Stock Units And Performance Share Units [Member]", "terseLabel": "RSUs and PSUs", "verboseLabel": "Restricted share units and performance share units" } } }, "localname": "RestrictedStockUnitsAndPerformanceShareUnitsMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "domainItemType" }, "bhvn_RevenueFromContractWithCustomerExcludingAssessedTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax", "label": "Revenue from Contract with Customer, Excluding Assessed Tax [Member]", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "domainItemType" }, "bhvn_RevenueParticipationRightTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Participation Right, Tranche One [Member]", "terseLabel": "Revenue Participation Right, tranche one" } } }, "localname": "RevenueParticipationRightTrancheOneMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RevenueParticipationRightTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Participation Right, Tranche Two [Member]", "terseLabel": "Revenue Participation Right, tranche two" } } }, "localname": "RevenueParticipationRightTrancheTwoMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_RightToPurchaseSecuritiesEquityInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right To Purchase Securities, Equity Interest, Percentage", "label": "Right To Purchase Securities, Equity Interest, Percentage", "terseLabel": "Right to purchase securities in specified future equity offering (as a percent)" } } }, "localname": "RightToPurchaseSecuritiesEquityInterestPercentage", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "percentItemType" }, "bhvn_RoyaltiesRevenuesPayableDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalties Revenues Payable During Period", "label": "Royalties Revenues Payable During Period", "negatedTerseLabel": "Royalty revenues paid and payable to RPI" } } }, "localname": "RoyaltiesRevenuesPayableDuringPeriod", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_SaleOfStockSharePurchasePremiumReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Share Purchase Premium Received", "label": "Sale Of Stock, Share Purchase Premium Received", "terseLabel": "Share purchase premium received" } } }, "localname": "SaleOfStockSharePurchasePremiumReceived", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_SalesBasedParticipationRightsValueSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales-Based Participation Rights, Value Sold", "label": "Sales-Based Participation Rights, Value Sold", "terseLabel": "Sales-based participation rights sold, value" } } }, "localname": "SalesBasedParticipationRightsValueSold", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ScheduleOfLeaseAssetsAndLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Lease Assets And Lease Liabilities", "label": "Schedule Of Lease Assets And Lease Liabilities [Table Text Block]", "terseLabel": "Schedule of Lease Assets and Liabilities" } } }, "localname": "ScheduleOfLeaseAssetsAndLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "bhvn_ScheduleOfLeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Lease Supplemental Cash Flow Information", "label": "Schedule Of Lease Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfLeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "bhvn_ScheduleOfLiabilityForSaleOfFutureRoyaltiesReductionToResearchAndDevelopmentExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Liability For Sale Of Future Royalties, Reduction To Research And Development Expense", "label": "Schedule Of Liability For Sale Of Future Royalties, Reduction To Research And Development Expense [Table Text Block]", "terseLabel": "Schedule of reduction to research and development expense" } } }, "localname": "ScheduleOfLiabilityForSaleOfFutureRoyaltiesReductionToResearchAndDevelopmentExpenseTableTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" ], "xbrltype": "textBlockItemType" }, "bhvn_ScheduleOfLiabilityForSaleOfFutureRoyaltiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Liability For Sale Of Future Royalties", "label": "Schedule Of Liability For Sale Of Future Royalties [Table Text Block]", "terseLabel": "Schedule of liability for sale of future royalties" } } }, "localname": "ScheduleOfLiabilityForSaleOfFutureRoyaltiesTableTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" ], "xbrltype": "textBlockItemType" }, "bhvn_ScheduleOfMilestonePaymentsOtherAgreementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Milestone Payments, Other Agreements", "label": "Schedule Of Milestone Payments, Other Agreements [Table Text Block]", "terseLabel": "Schedule of milestone payments for other agreements" } } }, "localname": "ScheduleOfMilestonePaymentsOtherAgreementsTableTextBlock", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTables" ], "xbrltype": "textBlockItemType" }, "bhvn_SeriesAPreferredSharesDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Preferred Shares Derivative Liability", "label": "Series A Preferred Shares Derivative Liability [Member]", "terseLabel": "Series A preferred shares derivative liability" } } }, "localname": "SeriesAPreferredSharesDerivativeLiabilityMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "bhvn_SeriesAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Preferred Shares", "label": "Series A Preferred Shares [Member]", "terseLabel": "Series A Preferred Shares" } } }, "localname": "SeriesAPreferredSharesMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SeriesBPreferredSharesDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Preferred Shares Derivative Liability", "label": "Series B Preferred Shares Derivative Liability [Member]", "terseLabel": "Series B preferred shares derivative liability" } } }, "localname": "SeriesBPreferredSharesDerivativeLiabilityMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "bhvn_SeriesBPreferredSharesForwardContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Preferred Shares Forward Contracts", "label": "Series B Preferred Shares Forward Contracts [Member]", "terseLabel": "Series B preferred shares forward contracts" } } }, "localname": "SeriesBPreferredSharesForwardContractsMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "bhvn_SeriesBPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Preferred Shares", "label": "Series B Preferred Shares [Member]", "terseLabel": "Series B Preferred Shares" } } }, "localname": "SeriesBPreferredSharesMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_ShareBasedAwardsWeightedAverageContractualTermAndAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Awards, Weighted Average Contractual Term And Aggregate Intrinsic Value", "label": "Share-Based Awards, Weighted Average Contractual Term And Aggregate Intrinsic Value [Abstract]", "terseLabel": "Weighted Average Contractual Term and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedAwardsWeightedAverageContractualTermAndAggregateIntrinsicValueAbstract", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "bhvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExpectedToVestNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested Expected To Vest, Number of Shares", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested Expected To Vest, Number of Shares", "terseLabel": "Unvested options expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExpectedToVestNumberOfShares", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "bhvn_ShareBasedCompensationAttributableToNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails": { "order": 2.0, "parentTag": "bhvn_ShareBasedCompensationAttributableToParent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Attributable To Noncontrolling Interest", "label": "Share-Based Compensation, Attributable To Noncontrolling Interest", "terseLabel": "Less: Share-based compensation expense attributable to non-controlling interests" } } }, "localname": "ShareBasedCompensationAttributableToNoncontrollingInterest", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ShareBasedCompensationAttributableToParent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Attributable To Parent", "label": "Share-Based Compensation, Attributable To Parent", "totalLabel": "Share-based compensation expense attributable to Biohaven Pharmaceutical Holding Company Ltd." } } }, "localname": "ShareBasedCompensationAttributableToParent", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_SharesIssuedEstimatedFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares Issued, Estimated Fair Value", "label": "Shares Issued, Estimated Fair Value", "terseLabel": "Estimated fair value of shares issued" } } }, "localname": "SharesIssuedEstimatedFairValue", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_SharesSubjectToMandatoryRedemptionAnnualInterestRateUponDefaultOfRedemptionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Subject To Mandatory Redemption, Annual Interest Rate Upon Default Of Redemption, Percentage", "label": "Shares Subject To Mandatory Redemption, Annual Interest Rate Upon Default Of Redemption, Percentage", "terseLabel": "Annual interest rate upon default of redemption (percent)" } } }, "localname": "SharesSubjectToMandatoryRedemptionAnnualInterestRateUponDefaultOfRedemptionPercentage", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhvn_SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceOptionalRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Optional Right", "label": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Optional Right", "terseLabel": "Redemption relative to original purchase price upon optional redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceOptionalRight", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceRequiredIfOptionNotElected": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Required If Option Not Elected", "label": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Required If Option Not Elected", "terseLabel": "Redemption relative to original purchase price upon required redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceRequiredIfOptionNotElected", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceRequiredRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Required Redemption", "label": "Shares Subject To Mandatory Redemption, Redemption Value Relative To Original Purchase Price, Required Redemption", "terseLabel": "Redemption relative to original purchase price upon required redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionRedemptionValueRelativeToOriginalPurchasePriceRequiredRedemption", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_SixthStreetFinancing2020DelayedDrawBasedOnMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing 2020 Delayed Draw Based On Milestone", "label": "Sixth Street Financing 2020 Delayed Draw Based On Milestone [Member]", "terseLabel": "Sixth Street Financing Agreement, Delayed Draw Based on Milestone" } } }, "localname": "SixthStreetFinancing2020DelayedDrawBasedOnMilestoneMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancing2020ImmediatelyAvailableDelayedDrawMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing 2020 Immediately Available Delayed Draw", "label": "Sixth Street Financing 2020 Immediately Available Delayed Draw [Member]", "terseLabel": "Sixth Street Financing Agreement, Immediately Available Delayed Draw" } } }, "localname": "SixthStreetFinancing2020ImmediatelyAvailableDelayedDrawMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancing2020SeniorTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing 2020 Senior Term Loan", "label": "Sixth Street Financing 2020 Senior Term Loan [Member]", "terseLabel": "Initial Term Loan" } } }, "localname": "SixthStreetFinancing2020SeniorTermLoanMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancing2021SeniorTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing 2021 Senior Term Loan", "label": "Sixth Street Financing 2021 Senior Term Loan [Member]", "terseLabel": "2021 Term Loan" } } }, "localname": "SixthStreetFinancing2021SeniorTermLoanMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing Agreement", "label": "Sixth Street Financing Agreement [Member]", "terseLabel": "Sixth Street Financing Agreement" } } }, "localname": "SixthStreetFinancingAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingAugust2020LoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing August 2020 Loans", "label": "Sixth Street Financing August 2020 Loans [Member]", "terseLabel": "August 2020 Loans", "verboseLabel": "Floating rate loans due August 2025 (10.00% at September 30, 2021)" } } }, "localname": "SixthStreetFinancingAugust2020LoansMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingDelayedDrawTermLoanOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing Delayed Draw Term Loan One", "label": "Sixth Street Financing Delayed Draw Term Loan One [Member]", "terseLabel": "DDTL-1" } } }, "localname": "SixthStreetFinancingDelayedDrawTermLoanOneMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingDelayedDrawTermLoanThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing Delayed Draw Term Loan Three", "label": "Sixth Street Financing Delayed Draw Term Loan Three [Member]", "terseLabel": "2021 DDTL Commitment" } } }, "localname": "SixthStreetFinancingDelayedDrawTermLoanThreeMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingDelayedDrawTermLoanTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing Delayed Draw Term Loan Two", "label": "Sixth Street Financing Delayed Draw Term Loan Two [Member]", "terseLabel": "DDTL-2" } } }, "localname": "SixthStreetFinancingDelayedDrawTermLoanTwoMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_SixthStreetFinancingSeptember2021LoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Financing September 2021 Loans", "label": "Sixth Street Financing September 2021 Loans [Member]", "terseLabel": "September 2021 Loans", "verboseLabel": "Floating rate loans due September 2026 (10.50% at June 30, 2022)(2)" } } }, "localname": "SixthStreetFinancingSeptember2021LoansMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "bhvn_StockIssuedDuringPeriodSharesShareBasedCompensationAndEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Share Based Compensation And Employee Stock Purchase Plan", "label": "Stock Issued During Period, Shares, Share Based Compensation And Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares under equity incentive plan and employee share purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationAndEmployeeStockPurchasePlan", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "bhvn_StockIssuedDuringPeriodValueShareBasedCompensationAndEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Share Based Compensation And Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Share Based Compensation And Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares under equity incentive plan and employee share purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationAndEmployeeStockPurchasePlan", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_SuccessBasedMilestonePaymentsBasedOnRegulatoryApprovalFactorOfFundedAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Success-Based Milestone Payments, Based On Regulatory Approval, Factor Of Funded Amount", "label": "Success-Based Milestone Payments, Based On Regulatory Approval, Factor Of Funded Amount", "terseLabel": "Success-based milestone payments based on regulatory approval, relative to funded amount" } } }, "localname": "SuccessBasedMilestonePaymentsBasedOnRegulatoryApprovalFactorOfFundedAmount", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_SuccessBasedMilestonePaymentsFirstZavegepantRegulatoryApprovalFactorOfFundedAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Success-Based Milestone Payments, First Zavegepant Regulatory Approval, Factor Of Funded Amount", "label": "Success-Based Milestone Payments, First Zavegepant Regulatory Approval, Factor Of Funded Amount", "terseLabel": "Success-based milestone payments based on first zavegepant regulatory approval, relative to funded amount" } } }, "localname": "SuccessBasedMilestonePaymentsFirstZavegepantRegulatoryApprovalFactorOfFundedAmount", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "decimalItemType" }, "bhvn_SuccessBasedMilestonePaymentsPeriodForPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Success-Based Milestone Payments, Period For Payment", "label": "Success-Based Milestone Payments, Period For Payment", "terseLabel": "Time period for success-based milestone payments" } } }, "localname": "SuccessBasedMilestonePaymentsPeriodForPayment", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhvn_TaldefgrobepAlfaLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taldefgrobep Alfa License Agreement", "label": "Taldefgrobep Alfa License Agreement [Member]", "terseLabel": "Taldefgrobep Alfa License Agreement" } } }, "localname": "TaldefgrobepAlfaLicenseAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_TemporaryEquitySharesIssuesConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity, Shares Issues, Consideration Received On Transaction", "label": "Temporary Equity, Shares Issues, Consideration Received On Transaction", "terseLabel": "Proceeds from shares issued" } } }, "localname": "TemporaryEquitySharesIssuesConsiderationReceivedOnTransaction", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period classified as temporary equity.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Preferred stock issued and sold (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bhvn_TemporaryEquityStockIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity, Stock Issued, Price Per Share", "label": "Temporary Equity, Stock Issued, Price Per Share", "terseLabel": "Shares issued price per share" } } }, "localname": "TemporaryEquityStockIssuedPricePerShare", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "perShareItemType" }, "bhvn_TransactionConsiderationAllocatedToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction Consideration Allocated To Equity", "label": "Transaction Consideration Allocated To Equity", "terseLabel": "Transaction consideration allocated to equity" } } }, "localname": "TransactionConsiderationAllocatedToEquity", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront Payment Received", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_YaleCollaborativeArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale Collaborative Arrangement", "label": "Yale Collaborative Arrangement [Member]", "terseLabel": "Yale Arrangement" } } }, "localname": "YaleCollaborativeArrangementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_YaleMoDEAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale MoDE Agreement", "label": "Yale MoDE Agreement [Member]", "terseLabel": "Yale MoDE Agreement" } } }, "localname": "YaleMoDEAgreementMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_YaleUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale University", "label": "Yale University [Member]", "terseLabel": "Yale University" } } }, "localname": "YaleUniversityMember", "nsuri": "http://www.biohavenpharma.com/20220630", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r53", "r116", "r117", "r265", "r310" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r243", "r244", "r245", "r246", "r264", "r309", "r356", "r358", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r604", "r606", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r243", "r244", "r245", "r246", "r264", "r309", "r356", "r358", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r604", "r606", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r181", "r244", "r245", "r341", "r344", "r557", "r603", "r605" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r181", "r244", "r245", "r341", "r344", "r557", "r603", "r605" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r238", "r243", "r244", "r245", "r246", "r264", "r309", "r346", "r356", "r358", "r388", "r389", "r390", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r604", "r606", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r238", "r243", "r244", "r245", "r246", "r264", "r309", "r346", "r356", "r358", "r388", "r389", "r390", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r604", "r606", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r52", "r53", "r116", "r117", "r265", "r310" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r184", "r185" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued Expense and Other Current Liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued commercialization and other professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r56", "r57", "r58", "r62", "r69", "r70", "r71" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Net unrealized investment gains (losses):" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r60", "r61", "r62", "r588", "r611", "r612" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r69", "r70", "r491", "r492", "r493", "r494", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r62", "r69", "r70", "r71", "r120", "r121", "r122", "r459", "r521", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income", "verboseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r55", "r62", "r69", "r70", "r71", "r459", "r492", "r493", "r494", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments:" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r120", "r121", "r122", "r400", "r401", "r402", "r472" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r360", "r404", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Non-cash share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "auth_ref": [ "r439", "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "terseLabel": "Stock issued in acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r112", "r169", "r173", "r179", "r207", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r452", "r460", "r489", "r522", "r524", "r564", "r586" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r36", "r112", "r207", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r452", "r460", "r489", "r522", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r475" ], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r193" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r194" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r190", "r214" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available-for-Sale Securities, Debt Maturities [Abstract]", "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract]", "terseLabel": "Net Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost", "terseLabel": "One year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value", "terseLabel": "One year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r187", "r191", "r214", "r569" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 }, "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]", "terseLabel": "Fair Value to Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Unaudited Interim Condensed Consolidated Financial Information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r355", "r357", "r430" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r355", "r357", "r426", "r427", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Issuance of shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r433", "r434", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Fair value of consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r101", "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Recognized gain on contingent value right" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r431", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "terseLabel": "Debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets, in progress research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r428", "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Amounts recorded:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Fair value of existing interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage", "terseLabel": "Post-transaction ownership percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Gain resulting from remeasurement of fair value of existing interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquired In-Process Research and Development" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r11", "r104" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r104", "r105" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash in the statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r99", "r490" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r19", "r20", "r21", "r109", "r112", "r136", "r137", "r142", "r144", "r146", "r154", "r155", "r156", "r207", "r250", "r254", "r255", "r256", "r259", "r260", "r307", "r308", "r312", "r316", "r323", "r489", "r625" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r443", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration, License and Other Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "License and other agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r570", "r593" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r240", "r241", "r242", "r247", "r616" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r120", "r121", "r472" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common shares, no par value; 200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 71,111,071 and 66,933,531 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r65", "r67", "r68", "r78", "r576", "r598" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Biohaven Pharmaceutical Holding Company Ltd." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r67", "r77", "r450", "r451", "r464", "r575", "r597" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: comprehensive loss attributable to non-controlling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r67", "r76", "r449", "r464", "r574", "r596" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r75", "r89", "r573", "r595" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r106", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r330", "r331", "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r330", "r331", "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liability, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r330", "r331", "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract liability, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was previously in contract liability" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r557" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r80" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r108", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r278", "r285", "r286", "r288", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r111", "r118", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r294", "r295", "r296", "r297", "r501", "r565", "r566", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r289", "r566", "r584" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Debt principal", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r261", "r294", "r295", "r499", "r501", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r43", "r292", "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43", "r262" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Contractual interest rate (percent)", "verboseLabel": "Contractual interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Liability For Sale of Future Royalties [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44", "r111", "r118", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r294", "r295", "r296", "r297", "r501" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Change of control" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r111", "r118", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r287", "r294", "r295", "r296", "r297", "r324", "r325", "r326", "r327", "r498", "r499", "r501", "r502", "r583" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetActivitywithinLiabilityAccountDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetReductiontoResearchandDevelopmentExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r274", "r290", "r294", "r295", "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r192", "r214", "r219", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r195" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Net Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Investments in continuous unrealized loss position for more than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "terseLabel": "Gross realized capital gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Gross realized capital losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r198", "r215", "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Aggregate fair value of available-for-sale debt securities in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r199", "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of available-for-sale debt securities in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Realized Gain (Loss)", "terseLabel": "Net realized capital (losses) gains" } } }, "localname": "DebtSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Transaction costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r102", "r166" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r53", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r49", "r50", "r53", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative contracts" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r362", "r363", "r394", "r395", "r397", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r189", "r347", "r354" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "U.S. corporate bonds", "verboseLabel": "Corporate bonds - U.S." } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r125", "r126", "r127", "r128", "r129", "r133", "r136", "r144", "r145", "r146", "r150", "r151", "r473", "r474", "r577", "r599" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - basic (in dollars per share)", "verboseLabel": "Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r125", "r126", "r127", "r128", "r129", "r136", "r144", "r145", "r146", "r150", "r151", "r473", "r474", "r577", "r599" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - diluted (in dollars per share)", "verboseLabel": "Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]", "terseLabel": "Other" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r147", "r148", "r149", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r490" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r393" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share-based compensation expense capitalized" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period for recognition of compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common shares", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r69", "r70", "r71", "r120", "r121", "r122", "r124", "r130", "r132", "r153", "r208", "r323", "r328", "r400", "r401", "r402", "r414", "r415", "r472", "r491", "r492", "r493", "r494", "r495", "r497", "r521", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r12", "r170", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r475", "r476", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r475", "r476", "r477", "r484", "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r276", "r294", "r295", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r476", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r483", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r475", "r476", "r478", "r479", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "terseLabel": "Schedule of carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried at adjusted cost or contract value" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r276", "r347", "r348", "r353", "r354", "r476", "r528" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r276", "r294", "r295", "r347", "r348", "r353", "r354", "r476", "r529" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r276", "r294", "r295", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r476", "r530" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Roll forward of aggregate fair value determined by Level 3 inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r480", "r486" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r480", "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of aggregate fair value of liability determined by Level\u00a03 inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Change in fair value of derivative liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Partial settlement of derivative liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesRollForwardofAggregateFairValueDeterminedbyLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r276", "r294", "r295", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r483", "r487" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r506", "r512", "r520" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r508", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows paid for interest portion of finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r504", "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails", "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r504" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Lease liabilities (current), Financing - Balance Sheet Location" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Financing Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r504" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Noncurrent finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Lease liabilities (noncurrent), Financing - Balance Sheet Location" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r507", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "verboseLabel": "Financing cash flows paid for principal portion of finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r503" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "totalLabel": "Total finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r506", "r512" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r506", "r512", "r520" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r503" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Right-of-use asset, Financing - Balance Sheet Location" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r517", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance lease" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r516", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r196", "r197", "r202", "r203", "r204", "r209", "r210", "r211", "r212", "r213", "r217", "r218", "r221", "r222", "r287", "r321", "r470", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r230", "r231", "r234", "r235", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r189", "r347" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]", "terseLabel": "Foreign corporate bonds", "verboseLabel": "Corporate bonds - Foreign" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r13", "r225", "r226", "r227", "r228", "r524", "r562" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r73", "r169", "r172", "r175", "r178", "r180", "r560", "r572", "r578", "r600" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r74", "r102", "r167", "r205", "r571", "r594" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Gain from equity method investment", "terseLabel": "Gain from equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r237", "r239" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r410", "r411", "r412", "r416", "r418", "r420", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r131", "r132", "r168", "r408", "r417", "r419", "r601" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses, other current liabilities, and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses, other current assets, and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r229", "r232" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r86", "r282", "r293", "r296", "r297" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedTerseLabel": "Interest expense on mandatorily redeemable preferred shares", "terseLabel": "Interest expense on mandatorily redeemable preferred shares", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r88", "r283", "r296", "r297" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense on mandatorily redeemable preferred shares" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r28" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails": { "order": 2.0, "parentTag": "bhvn_InventoryCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r33", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "verboseLabel": "Total inventories classified as current" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Less noncurrent inventories" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r29" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails": { "order": 1.0, "parentTag": "bhvn_InventoryCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r84" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "bhvn_InvestmentIncomeExcludingRealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Gross investment income from debt securities available-for-sale" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r87", "r602" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "bhvn_InvestmentIncomeExcludingRealizedGainLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "negatedTerseLabel": "Investment expenses" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r84", "r86" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "totalLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Income, Net [Abstract]", "terseLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeTextBlock": { "auth_ref": [ "r84", "r86", "r87", "r602" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table Text Block]", "terseLabel": "Schedule of net investment income" } } }, "localname": "InvestmentIncomeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of available-for-sale debt securities by contractual maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r475" ], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r201", "r561", "r580", "r614", "r632" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r102" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of common shares as payment for license agreement" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r518", "r520" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Finance Lease, Description [Abstract]", "terseLabel": "Finance leases:" } } }, "localname": "LesseeFinanceLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Vehicle lease, term" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r519" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Real estate lease, remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r112", "r174", "r207", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r453", "r460", "r461", "r489", "r522", "r523" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r112", "r207", "r489", "r524", "r568", "r591" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r42", "r112", "r207", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r453", "r460", "r461", "r489", "r522", "r523", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License agreement" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining credit facility capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r275", "r291", "r294", "r295", "r566", "r587" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Repayments of debt principal" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r118", "r248", "r280" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r118", "r248", "r280" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r118", "r248", "r280" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r118", "r248", "r280" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r118" ], "calculation": { "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021 (remaining three months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtRepaymentsofDebtPrincipalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r249" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r48", "r112", "r207", "r250", "r254", "r255", "r256", "r259", "r260", "r489", "r567", "r590" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests in consolidated subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r100", "r103" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r66", "r71", "r131", "r132", "r456", "r463" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interests", "negatedTerseLabel": "Net loss attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r125", "r126", "r127", "r128", "r133", "r134", "r143", "r146", "r169", "r172", "r175", "r178", "r180" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd., basic", "totalLabel": "Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd." } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r135", "r138", "r139", "r140", "r141", "r143", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd., diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Future Adoption of New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r120", "r121", "r122", "r328", "r447" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r62", "r72" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r169", "r172", "r175", "r178", "r180" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r513", "r520" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r504" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails", "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r504" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Lease liabilities (current), Operating - Balance Sheet Location" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r504" ], "calculation": { "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r509", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r503" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Right-of-use asset, Operating - Balance Sheet Location" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r517", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r516", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses and other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r14", "r563", "r585" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r67", "r69", "r70", "r72", "r75", "r323", "r491", "r496", "r497", "r573", "r595" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss, net of tax", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r64", "r67", "r449", "r450", "r458" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r449", "r450", "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Tax on other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]", "terseLabel": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Mandatorily Redeemable Preferred Shares, net" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r34", "r224" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-allotment option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Paid-in-kind interest" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Biohaven Shareholders' Equity (Deficit)" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Other offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r90", "r92", "r188" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r93" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedTerseLabel": "Payment for IPR&D asset acquisition" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r94" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payment for intangible asset", "terseLabel": "Payment for license agreement" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r94", "r439", "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Upfront cash payment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Deemed dividend upon repurchase of preferred shares in consolidated subsidiary", "negatedTerseLabel": "Deemed dividend upon repurchase of preferred shares in consolidated subsidiary" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (share)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r34", "r223", "r224" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current [Abstract]", "terseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpenseCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPrepaidExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common shares", "verboseLabel": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r96" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from the issuance of series B preferred shares" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Net proceeds from term loan" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r95", "r399" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of share options" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r90", "r91", "r188" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r90", "r91", "r188" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales", "verboseLabel": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r63", "r66", "r71", "r98", "r112", "r123", "r131", "r132", "r169", "r172", "r175", "r178", "r180", "r207", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r449", "r455", "r457", "r463", "r464", "r474", "r489", "r578" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r236", "r524", "r581", "r592" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r62", "r72" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r303", "r304", "r305", "r306" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Contingently redeemable non-controlling interests" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r407", "r556", "r619" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r11", "r105" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash (included in other current assets)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r14", "r105", "r615" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash (included in other assets)" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsCashandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r328", "r524", "r589", "r610", "r612" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r120", "r121", "r122", "r124", "r130", "r132", "r208", "r400", "r401", "r402", "r414", "r415", "r472", "r607", "r609" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r164", "r165", "r171", "r176", "r177", "r181", "r182", "r183", "r340", "r341", "r557" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r107", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r515", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r515", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Gross proceeds from transaction" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Issuance price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r62", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of activity in accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of available-for-sale debt securities from amortized cost to fair value" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r426", "r427", "r430" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of reconciliation of total cash, cash equivalents and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsRPIAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax provision and effective tax rate" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r44", "r118", "r294", "r296", "r324", "r325", "r326", "r327", "r498", "r499", "r502", "r583" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Summary of borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r136", "r137", "r144", "r146", "r151" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r392", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of non-cash share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of required repayments of debt principal" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.", "label": "Schedule of Realized Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of proceeds from sale of available-for-sale debt securities and related gross realized capital gains and losses" } } }, "localname": "ScheduleOfRealizedGainLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r359", "r361", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of RSU activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r366", "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": { "auth_ref": [ "r299", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Represents settlement terms for the group of mandatorily redeemable securities, including the description and the details of all terms for each outstanding financial instrument and each settlement option.", "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]", "terseLabel": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]" } } }, "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionTable": { "auth_ref": [ "r299", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the description and the details of all terms for each outstanding financial instrument and each settlement option, including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, \"the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share\") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments is disclosed separately from the amount of retained earnings or accumulated deficit).", "label": "Schedule of Financial Instruments Subject to Mandatory Redemption [Table]", "terseLabel": "Schedule of Financial Instruments Subject to Mandatory Redemption [Table]" } } }, "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of changes in shareholders' equity (deficit)" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Senior secured debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails", "http://www.biohavenpharma.com/role/DebtSummaryofBorrowingsDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialInstrumentsNotMeasuredatFairValueDetails", "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r19", "r20", "r323" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A preferred shares" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails": { "order": 1.0, "parentTag": "bhvn_ShareBasedCompensationAttributableToParent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Non-cash share-based compensation expense", "verboseLabel": "Total non-cash share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service period of award (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationNonCashExpenseDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share-based award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending (in shares)", "periodStartLabel": "Unvested, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending (in dollars per share)", "periodStartLabel": "Unvested, beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of RSUs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationRestrictedShareUnitsandPerformanceShareUnitsDetails", "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Issuance price per share (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Share-based award term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of options exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of options outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of options vested and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Common stock sold, price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionBySettlementTermsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Line Items]", "terseLabel": "Mandatorily Redeemable Preferred Shares" } } }, "localname": "SharesSubjectToMandatoryRedemptionBySettlementTermsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "stringItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock": { "auth_ref": [ "r299", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, \"the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share\") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit).", "label": "Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block]", "terseLabel": "Schedule of activity within the preferred share liability" } } }, "localname": "SharesSubjectToMandatoryRedemptionDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": { "auth_ref": [ "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur.", "label": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]", "terseLabel": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]" } } }, "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetNarrativeDetails", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetTables" ], "xbrltype": "domainItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": { "auth_ref": [ "r301" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current", "terseLabel": "Current portion of mandatorily redeemable preferred shares" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent": { "auth_ref": [ "r301" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent", "terseLabel": "Mandatorily redeemable preferred shares, net", "totalLabel": "Net balance at period end" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/MandatorilyRedeemablePreferredSharesnetActivityWithinthePreferredShareLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r109", "r112", "r136", "r137", "r142", "r144", "r146", "r154", "r155", "r156", "r207", "r250", "r254", "r255", "r256", "r259", "r260", "r307", "r308", "r312", "r316", "r323", "r489", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r47", "r69", "r70", "r71", "r120", "r121", "r122", "r124", "r130", "r132", "r153", "r208", "r323", "r328", "r400", "r401", "r402", "r414", "r415", "r472", "r491", "r492", "r493", "r494", "r495", "r497", "r521", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r120", "r121", "r122", "r153", "r557" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r20", "r21", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common shares as part of acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r323", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issued (shares)", "verboseLabel": "Issuance of common shares, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesnetNarrativeDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of common shares as payment for assets (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r323", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common shares under equity incentive plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r323", "r328", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r47", "r323", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common shares as part of acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r323", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Issuance of common shares as payment for assets", "verboseLabel": "Issuance of common shares as payment for agreements" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r328", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common shares under equity incentive plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r112", "r186", "r207", "r489", "r524" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodStartLabel": "Beginning of period balance", "terseLabel": "End of period balance", "totalLabel": "Total shareholders\u2019 deficit attributable to Biohaven Pharmaceutical Holding Company Ltd." } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r70", "r112", "r120", "r121", "r122", "r124", "r130", "r207", "r208", "r328", "r400", "r401", "r402", "r414", "r415", "r447", "r448", "r462", "r472", "r489", "r491", "r492", "r497", "r521", "r608", "r609" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/ShareholdersDeficitChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r328", "r329", "r471" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "verboseLabel": "Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r196", "r197", "r202", "r203", "r204", "r287", "r321", "r470", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsBMSAgreementandAmendmentDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsOtherAgreementsDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsPfizerCollaborationDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/CollaborationLicenseandOtherAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/ShareholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r347", "r579", "r613" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "Government related obligations - U.S." } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r115", "r347", "r354", "r579" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury bills" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r157", "r158", "r159", "r160", "r161", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Warrants to purchase common shares" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r146" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding - diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r133", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding - basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=118255708&loc=SL5909891-110878" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498357-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r561": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r614": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r620": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r621": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r623": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r624": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r625": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r626": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r627": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r630": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r631": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r632": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r633": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" } }, "version": "2.1" }